SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a major trending topic as its Q4 earnings, which beat expectations, were met with a significant stock dip, fueling intense debate among investors. The community is sharply divided, with many viewing the sharp decline as a prime 'buy the dip' opportunity for a long-term hold, citing strong fundamentals. Conversely, bears are expressing concerns over cautious guidance, the implications of its Warner Bros. Discovery acquisition, increased content spending, and the pausing of share buybacks.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is a hot topic as the community anticipates significant announcements, fueled by recent industry awards and confirmation of continued work with Celestial AI, now part of Marvell. Discussion centers on POET's patented optical interposer technology, seen as a crucial solution for the escalating demand for high-speed, power-efficient optical interconnects in AI data centers. Many believe the company is poised for major customer orders, positioning it as a key player in the ongoing optical supercycle.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as gold surges, fueled by escalating geopolitical tensions, including discussions around Trump's tariff threats against European nations and the Greenland issue. The community is actively debating if this signifies a sustained shift towards real assets due to eroding trust in fiat currencies, or if it's a momentum-driven rally susceptible to de-escalation.

America's Oil Reserve for the Digital Age

U.S Oil

USOR CRYPTO is experiencing a highly polarized trend following a rapid price surge, sparking intense community debate. While many celebrate substantial gains and anticipate further rallies, a vocal segment warns of a potential "rug pull" or pump-and-dump, cautioning investors due to its meme coin characteristics. Amidst this volatility, new participants are actively seeking information on how to acquire the token.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is actively discussed amid its upcoming separation into two independent companies and the appointment of a new CEO, with many anticipating this will unlock significant value. Community sentiment is polarized between those who see current price levels as a rare buying opportunity and those concerned about it being a "value trap," often fueled by claims of market manipulation and recent analyst downgrades.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust (SPY) is actively trending amid heightened geopolitical rhetoric, particularly surrounding discussions of a potential U.S. acquisition of Greenland and associated tariff implications. The community is sharply divided, with many anticipating a significant rebound from a recent market dip, while others express concerns about escalating global tensions and upcoming public statements from a prominent political figure. Broader market sentiment is currently influenced by a tug-of-war between 'buy the dip' enthusiasm and fears of further instability affecting international asset holdings.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following significant insider share purchases, including CEO Ryan Cohen's acquisition of 500,000 shares. This has ignited strong bullish sentiment within the community, with many interpreting the buys as a powerful signal of conviction and a potential catalyst for a renewed short squeeze. Investors are actively discussing the company's strong balance sheet and lack of debt, anticipating a major move for the meme stock.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is experiencing significant volatility, with recent analyst downgrades sparking accusations of market manipulation and creating confusion among investors despite the company's strong AI server demand and increased revenue guidance. While many in the community view the recent price dip as a prime buying opportunity given its low valuation and record AI server backlog, others remain cautious amid concerns over memory price inflation and competitive pressures in the AI infrastructure market.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF (DIA) is trending due to renewed tariff threats from a US political figure concerning an international territory, fueling global trade war fears. This has sparked widespread community discussion, with many anticipating significant market volatility and potential capital flight, while others remain optimistic about a swift market rebound amid broader geopolitical tensions.

Virtu Financial, Inc. engages in the provision of trading solutions and liquidity services. It operates through the following segments: Market Making, Execution Services, and Corporate. The Market Making segment involves the cash, futures, and options markets across global equities, fixed income, currencies, cryptocurrencies, and commodities. The Execution Services segment includes agency-based, execution-only trading, workflow technology, and trading analytics. The Corporate segment consists of investments in financial services-oriented opportunities and maintains corporate overhead expenses and all other income and expenses that are not attributable to the other segments. The company was founded by Vincent J. Viola and Douglas A. Cifu in 2008 and is headquartered in New York, NY.

Virtu Financial Inc - Ordinary Shares - Class A

Virtu Financial is trending due to robust earnings reports that have consistently exceeded expectations, fueled by sustained market volatility and high trading volumes, including growing crypto market participation. While many are optimistic about its market-making operations, a vocal community segment remains critical, often linking the company to allegations of market manipulation and ongoing lawsuits. This dual narrative highlights intense, contrasting discussions surrounding its operational success and perceived controversies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?

JNJ heads into Q4 earnings with strong pharma and MedTech momentum, offset by Stelara biosimilar pressure and China-related headwinds.

Teva Pharmaceutical Industries Ltd. $TEVA Stock Holdings Lifted by Harel Insurance Investments & Financial Services Ltd.

Harel Insurance Investments & Financial Services Ltd. lifted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 12.9% in the 3rd quarter, according to the company in its...

Wall Street Zen Downgrades Teva Pharmaceutical Industries (NYSE:TEVA) to Buy

Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research note on Sunday...

ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now?

ANI Pharmaceuticals' rare disease growth, led by surging Cortrophin Gel sales, is outpacing Teva's slower sales momentum in this head-to-head stock comparison.

Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Commonwealth Equity Services LLC Acquires 122,701 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Commonwealth Equity Services LLC raised its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 75.3% during the third quarter, according to its most recent filing with the...

Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 52-Week High - Time to Buy?

Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 52-Week High - Here's What Happened...

TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug

Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.

Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

<ul class="summary-bullets"><li>TEV-408 is an antibody designed to block IL-15, a protein that plays a major role in driving immune-related diseases.</li><li>Teva expects 2025 revenues in the lower end of the $16.8–$17.0 billion range</li><li>TEVA stock is on track to open at its highest levels since July 2017.</li></ul>Shares of Teva Pharmaceuticals Industries (TEVA) rose more than 6% in premarket trading on Monday, after the company announced a funding agreement with Royalty Pharma (RPRX) of up to $500 million to advance Teva’s anti-IL-15 antibody, TEV-‘408, across its clinical programs.TEV-408 is Teva’s experimental antibody designed to block IL-15, a protein that plays a major role in driving immune-related diseases.<a href="https://stocktwits.com/symbol/TEVA">TEVA stock</a> is on track to open at its highest levels since July 2017.<h2 class="st-heading-2">Terms Of The Agreement</h2>The initial funding includes $75 million to support a Phase 2b study in vitiligo, an autoimmune condition that causes the loss of skin pigmentation, resulting in white patches. Royalty Pharma holds an option to provide an additional $425 million to co-fund Phase 3 development based on Phase 2b results.Under the agreement, milestone payments and royalties on worldwide net sales would be payable to Royalty Pharma if TEV-‘408 is approved and launched.The TEV-‘408 therapy is currently in Phase 1b for vitiligo and Phase 2a for celiac disease and has received Fast Track designation from the U.S. Food and Drug Administration (FDA). By blocking IL-15, TEV-‘408 aims to reduce immune-mediated destruction of melanocytes in vitiligo and intestinal inflammation in celiac disease.“This agreement with Royalty Pharma enables us to advance our science more efficiently and accelerate our pipeline to deliver meaningful solutions for patients worldwide. Vitiligo represents a significant unmet need, with only one approved topical treatment currently available and no systemic options. We are dedicated to driving scientific progress that brings new, effective therapies to people living with chronic autoimmune diseases,” said Richard Francis, Teva’s President and CEO.Teva expects 2025 revenues in the lower end of the $16.8–$17.0 billion range, flat to slightly lower in 2026, low-single-digit growth in 2027, and at a mid-single-digit compound annual growth rate through 2030.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the pre-market gain, retail sentiment on Stocktwits for TEVA turned ‘bearish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.One user sees the stock climbing to $40. It is currently at $33.8.<stembedurl>https://stocktwits.com/OX50/message/641481558</stembedurl>Over the past year, TEVA shares have gained over 50%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-inbs-stock-surging-again-today/cmUaGlNR4EJ">INBS Stock Has Surged Over 330% So Far In January – But Retail Traders Are Warning Of A Pullback</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Teva Pharmaceutical Industries’ logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Why Is TEVA Stock Rising Pre-Market Today?

Teva announced a funding agreement with Royalty Pharma of up to $500 million to advance its anti-IL-15 antibody, TEV-‘408, across its clinical programs.

Equity

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva- Pharmaceutical Industries Ltd. - ADR

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$31.36
Prev Close	$31.76
Open	$30.78
Dividend Yield	0.00%
50-Day Moving Average	$28.81
Beta	0.80
Avg. Volume	8.94M
PE Ratio	51.22

52-Week High	$33.42
52-Week Low	$12.47
Market Capitalization	$35.96B
EPS (Annual)	-$1.46
Price to Book	4.96
Revenue Per Employee	$458,660.10
Enterprise Value/EBITDA	N/A

TEVA
Teva- Pharmaceutical Industries Ltd. - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TEVA News

TEVATeva- Pharmaceutical Industries Ltd. - ADR